Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial
Sci Adv. 2025 Jul 4;11(27):eadw0896. doi: 10.1126/sciadv.adw0896. Epub 2025 Jul 4. ABSTRACT COVID-19 continues causing substantial mortality despite existing FDA-approved COVID-19 vaccines. An effective COVID-19 …